anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE OF REVIEW: Direct oral anticoagulants (DOACs) are increasingly prescribed for prevention of thromboembolic events. Thus, trauma care providers are facing a steadily raising number of injured patients on DOACs.
RECENT FINDINGS: Despite a predictable pharmacokinetic profile, the resulting plasma levels of trauma patients upon admission and bleeding risks remain uncertain. Therefore, recent guidelines recommend the measurement of DOAC plasma concentrations in injured patients. Alternatively, DOAC specific visco-elastic tests assays can be applied to identify DOAC patients at bleeding risk.Bleeding complications in trauma patients on DOACs are generally higher compared to nonanticoagulated subjects, but comparable to vitamin K antagonists (VKAs). In particular, a traumatic brain injury does not carry an increased risk of intracranial bleeding due to a DOAK intake compared to VKAs. Current studies demonstrated that up to 14% of patients with a hip fracture are on DOACs prior to surgery. However, the majority can be operated safely within a 24h time window without an increased bleeding rate.Specific antagonists facilitate rapid reversal of patients on DOACs. Idarucizumab for dabigatran, and andexanet alfa for apixaban and rivaroxaban have been approved for life threatening bleeding. Alternatively, prothrombin complex concentrate can be used. Dialysis is a potential treatment option for dabigatran and haemoabsorption with special filters can be applied in patients on FXa-inhibitors.
SUMMARY: Current guidelines recommend the measurement of DOAC plasma levels in trauma patients. Compared to VKAs, DOACs do not carry a higher bleeding risk. DOAC specific antagonists facilitate the individual bleeding management.
Patients will undergo a treatment plan determined by the multidisciplinary team. This involves four cycles of intravenous (IV) doxorubicin at a dose of 60 mg/m2 along with IV cyclophosphamide at 600 mg/m2 per cycle. Following this, taxane will be administered. Additionally, patients will take placebo tablets three times daily.
The present invention relates to traumata ulcer ingot, which is produced with the following raw materials in weight proportions: 10 to 20 proportions of pearl, 5 to 10 proportions of calomel and 5 to 10 proportions of borneol. The pearl particles are firstly put into a closed vessel, which is then baked over a fire. The closed vessel is shaken continuously during the bake process. The closed vessel is taken from the fire and natural cooling is performed. The pearl particles become baked pearl; various raw materials are mixed and ground. The product can be obtained by filtering the mixture with a screen with a filtering size ranging from 100 to 150 meshes. The present invention has the remarkable advantages that: 'platinum ingot' produced by adopting the method provided by the present invention has rapid and strong detumescence, acesodyne and ulcer elimination effect in curing skin infect and ulcer. The 'platinum ingot' can quickly alleviate anguish of sufferer with a cure rate reaching 100 percent.
Avapritinib was not mutagenic in a 6-month transgenic mouse study up to the highest dose evaluated at 20 mg/kg/day. Avapritinib was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test). Avapritinib was positive in the in vitro chromosome aberration test in human peripheral blood lymphocytes but negative in the in vivo rat bone marrow micronucleus test, and overall non-genotoxic.

There were no direct effects on fertility in rats of either sex in a dedicated fertility and early embryonic development study. Avapritinib may impair spermatogenesis and adversely affect early embryogenesis. Reduction in sperm production and testicular weight were observed in rats and hypospermatogenesis in dogs administered avapritinib at exposure of 8.7 times and 0.5 time the 300 mg human dose, respectively. Avapritinib partitioned into seminal fluids up to 0.2 times the concentration found in human plasma at 300 mg. In female rats there was an increase in pre-implantation loss at exposure of 5.4 times the human exposure at 300 mg and in early resorptions at exposure 2.7 times the human exposure at 300 mg with an overall decrease in viable embryos. Cystic degeneration of corpora lutea and vaginal mucification was also observed in female rats administered avapritinib for up to 6 months at exposure 1.3 times the human exposure based on AUC at the 300 mg dose.
PURPOSE: A thermosensitive composition, solution, film, sponge and powder for preventing adhesion comprising a living body-induced polymer and a thermosensitive PEG-PPG-PEG block copolymer are provided. It reduces or prevents surgical adhesions during and/or after the operation and is low in foreign body response. CONSTITUTION: The thermosensitive composition for preventing adhesion comprises 0.1 to 10% by weight of a living body-induced polymer, 1 to 20% by weight of a thermosensitive PEG-PPG-PEG block copolymer and 50 to 97% by weight of physiological saline. The living body-induced polymer is selected from the group consisting of chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, hyaluronic acid, collagen, gelatin, elastin and fibrin. The composition gelation by body temperature causes slow release of a drug. It is topically sprayed, injected or compressed on a wound site during and after the operation.
FIELD: medicine. ^ SUBSTANCE: invention refers to biotechnology and genetic engineering. DNA is delivered to macroorganism in biocompatible and biodegradable microcapsules made of multilayer polymeric DEAE-dextrane/k-carrageenan membranes protecting DNA from nuclease splitting while delivered to organism cells. Plasmid DNA is sorbed with porous particles CaCO3 by coprecipitating process. The multilayer membranes are produced by sequential layer of DEAE-dextrane and k-carrageenan on the porous particles CaCO3. The microcapsules are placed in 0.1 M EDTA solution. It is agitated at an intensive rate to dissolve an internal core containing CaCO3. The produced microcapsules are washed with water for three times. They are injected in animal cells. ^ EFFECT: method increases an amount of sorbed DNA to 96,0-99,1 % and provides greater strength of the microcapsule membrane. ^ 3 tbl, 2 ex
The present invention generally relates to anti-microbial formulations and methods of their use and production. The formulations of the present invention are effective as broad spectrum anti-bacterial agents with efficacy against both Gram-negative and Gram-positive bacteria, as anti-viral agents with efficacy against both enveloped and non-enveloped viruses, and as anti-fungal agents with efficacy against both vegetative and spore forms of microorganisms and against biofilms. The present invention includes anti-microbial compositions that have at least one surfactant, at least one acid, at least one peroxide (preferably hydrogen peroxide), peracetic acid, and water. The anti-microbial Formulations of the present invention may additionally contain an organic salt. The organic salt may be a salt of the same acid that is used in the Formulation or a salt of a different acid. Methods for production and use of the inventive compositions are disclosed.
Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
We conducted a systematic review and network meta-analyses evaluating the effects of different intraoperative vasoactive drugs on acute kidney injury (AKI) and other perioperative outcomes in adult liver transplant recipients. We searched multiple electronic databases using words from the "liver transplantation" and "vasoactive drug" domains. We included all randomized controlled trials conducted in adult liver transplant recipients comparing 2 different intravenous vasoactive drugs or 1 against a standard of care that reported AKI, intraoperative blood loss, or any other postoperative outcome. We conducted 4 frequentist network meta-analyses using random effect models, based on the interventions' mechanism of action, and evaluated the quality of evidence (QoE) using Grading of Recommendations, Assessment, Development, and Evaluations recommendations. We included 9 randomized controlled trials comparing different vasopressor drugs (vasoconstrictor or inotrope), 3 comparing a somatostatin infusion (or its analogues) to a standard of care, 11 comparing different vasodilator infusions together or against a standard of care, and 2 comparing vasoconstrictor boluses at graft reperfusion. Intravenous clonidine was associated with shorter duration of mechanical ventilation, intensive care unit, and hospital length of stay (very low QoE), and some vasodilators were associated with lower creatinine level 24 h after surgery (low to very low QoE). Phenylephrine and terlipressin were associated with less intraoperative blood loss when compared with norepinephrine (low and moderate QoE). None of the vasoactive drugs improve any other postoperative outcomes, including AKI. There is still important equipoise regarding the best vasoactive drug to use in liver transplantation for most outcomes. Further studies are required to better inform clinical practice.
The World Health Organization listed vaccine hesitancy as one of the leading threats to global health in 2019. Vaccine hesitancy is defined as the "reluctance or refusal to vaccinate despite the availability of vaccines". Given the novelty of the COVID-19 pandemic, hesitancy towards use of COVID-19 vaccine may be linked to the process of vaccine development and clinical trial validation of safety and/or efficacy, rather than hesitations regarding vaccines in general. This has already inspired several education campaigns. It is unclear whether education leads to reduced hesitance and whether reduced hesitance leads to increased intent to vaccinate. Further, early surveys demonstrating high COVID-19 vaccine acceptance and intent to vaccinate may not reflect actual uptake, as shown by comparisons to flu vaccination uptake at a time when flu vaccines are both available, validated and largely freely accessible. Inspiring vaccine confidence is a multifaceted challenge, and the COVID-19 pandemic has shed light on one of its aspects, specifically the public health approach to health information dissemination. The lack of evidence-based knowledge and preparedness coupled with pandemic fatigue impacts the uptake of recommended health behaviours and puts human lives at risk. Different people adopt different responses to health promotion materials based on a variety of socioeconomic factors. For example, in an American study on vaccination in children, it was found that children who had never received a vaccine tended to come from affluent, college educated families, while those who had only received some recommended vaccinations came from minority families that were single parent, low-income and less likely to have completed higher education. Almost 50% of the parents of the unvaccinated children cited concerns about vaccine safety. The strength of beliefs leading to hesitancy may change the ability to affect intent to vaccinate. These beliefs may be contributed to by cultural dimensions in Canada and cultures of recently immigrated individuals, with regards to individualism, collectivism, perceptions of social benefits, etc. These factors might also impact the choice to vaccinate. The existence of many outlets for highly varied information underscores the need for unbiased and credible education on COVID-19 vaccinations. The investigators aim to study whether education, in the form of three two-minute educational videos about COVID-19 vaccine development and dissemination, reduces vaccine hesitancy and increases intent to vaccinate. The investigators intend to use insights from this research study to develop a framework for video-based 'education prescriptions' that reduce vaccine hesitancy and increase intent to vaccinate across a number of infectious diseases. This may have wide-ranging impact: inform practice for health promotions and public health, as well as support infectious disease related work done by healthcare professionals (e.g. those working in travel medicine, where vaccination rates are also low).
<P>PROBLEM TO BE SOLVED: To provide an embedding type medical device which has broad thrombolysis characteristics.  <P>SOLUTION: The medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention relates to a wind-cold influenza capsule. Medicine powder in the capsule by parts of weight is 0.5 part to 1.8 parts of ephedra, 0.5 part to 1.8 parts of cassia twig, 0.8 part to 3.6 parts of radices sileris and 0.8 part to 2.5 parts of schizonepeta. The capsule is a combination formed by mixing raw medicines or medicinal slices. 1 part to 2.5 parts of rhizoma seu radix notopterygli, 1 part to 2.5 parts of radix angelicae pubescentis, 0.5 part to 2.6 parts of radix angelicae, 0.8 part to 2.5 parts of tussilago, 0.8 part to 1.8 parts of almond, 1 part to 2.5 parts of lily, 0.8 part to 2.6 parts of radix stemonae, 0.1 part to 0.3 part of aserum and 0.5 part to 1.8 parts of glycyrrhiza can be added into the combination. The wind-cold influenza capsule has obvious effects on slight or severe wind-cold influenza and patients with severe cough, effective rate is more than 99%, and cure rate is more than 95 %. The wind-cold influenza capsule is free of auxiliary materials, cannot scatter qi, has no effects on work and life, and is free of toxic effect, convenient to take and suitable for various wind-cold influenza diseases.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including TREXIMET, in pregnant women at about 30 weeks gestation and later. NSAIDs, including TREXIMET, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including TREXIMET, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit TREXIMET use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if TREXIMET treatment extends beyond 48 hours. Discontinue TREXIMET if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific Populations (8.1)].
Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
Liver fatty acid binding protein (L-FABP) is an abundant cytosolic lipid-binding protein that regulates lipid transport and metabolism. Only one common non-synonymous polymorphism (A227G) leading to an amino-acid exchange in the exonic region of the L-FABP gene has been previously identified. Experimental elevations of free fatty acids (FFAs) have been shown to impair insulin mediated suppression of endogenous glucose production (EGP). Deletion of the L-FABP gene shows no obvious phenotype in mice receiving a low fat chow diet, but leads to decreased hepatic triglyceride accumulation in the prolonged fasted state, which exposes mice to an increased fatty acid flux to the liver. The function of the L-FABP gene may be altered by polymorphisms in coding regions of the gene, probably leading to modifications in hepatic triglyceride accumulation and hepatic insulin resistance.We hypothesize that carriers of the A277G SNP, when compared to matched wild-type subjects, may show altered responses of hepatic glucose production upon exposure to increased peripheral fatty acid concentrations, as achieved by lipid / heparin infusions. Because it is known that free fatty acids potently increase insulin secretion, we use somatostatin clamps in our experiments, followed by replacement of postabsorptive insulin and glucagon concentrations.
stress urinary incontinence is a frequent condition that can be caused by urethral sphincter insufficiency and results in a dramatic deterioration of the quality of life. We developed a new therapeutic strategy for stress urinary incontinence based on the implantation myofibers with their satellite cells. The principle of this procedure relies on the activation in vivo of the satellite cells present around each myofibers. Satellite cell activation is concomitant with myofiber death that occurs after their implantation. Activated satellite proliferate and fuse to form myotubes replacing the parental myofibers thus leading to the reconstitution of the muscle mass that was initially implanted. Preliminary studies in the pig showed the regenerated muscle tissue in the urethra was innervated by urethral nerves and developed tonic contractions acting like a new sphincter. This procedure does not include a phase of satellite cell amplification ex vivo, as standard methods of satellite cell transfer, and rather relies on the natural myogenic capacities of these cells. Thus, the procedure of cell transfer into the urethra is considerably simplified and can be performed in one step in the operating room.This therapeutic strategy could represent an alternative to the artificial urinary sphincter.
PURPOSE:To obtain a bathing agent composition having extremely excellent warmth maintaining effects, wetting effects on skin, beautifying effects and deodorant effects, using a relatively readily obtainable plant component, containing Myrica rubra Sieb. et Zucc. CONSTITUTION:A bathing agent composition which contains Myrica rubra Sieb. et Zucc., preferably one or more of dried ground substance of root, fruit, bark and leaf of Myrica rubra Sieb. et Zucc., juice, dried substance of a mixture thereof as an essential component in an amount of 0.1-80pts.wt. Myrica rubra Sieb. at Zucc. based on 100pts.wt. total amount of the bathing agent composition, 10-80pts.wt. dried ground substance, 0.1-50pts.wt. juice and/dried substance of juice or 0.1-30pts.wt. extracted solution and/or powder of extracted solution, showing excellent bathing effect, is stable and is not observed to have deterioration in quality even in long-term preservation and has good compatibility with other components.
PURPOSE:The titled material useful for closed blood vessel therapy, biopsy, etc., having high activity retention ratio, improved non-dispersibility, being processed into rapidly injectable sol state, obtained by immobilizing a physiologically active substance to a carrier consisting of a specific high polymer substance. CONSTITUTION:A physiologically active substance is immobilized to a carrier of laminae having <=5,000mu, preferably 200-1,000mu longer diameter, <=3,000mu, preferably 200-800mu shorter diameter, and <=2,000mu, preferably <=800mu thickness or fibers having <=30 denier, preferably 0.5-15 denier single fiber fineness, <=3mm., preferably <1mm. fiber length using a high polymer substance having >=50wt% water absorption ratio as a material. Gelatin, chitin, collagen, etc. is preferable used as the material. The material is processed into a rapidly injectable sol state when it is blended with a medium such as water, etc., and it can reduce side effects of the physiologically active substance and be made into aerosol while keeping its activity.
Participants were randomized to receive an arm. In this arm, participants consumed with control jelly at 3.5 g/kg body weight. Consumption was taken at Burapha University.
Older individuals are more likely to die or become ill during heat waves. During the 1995 Chicago heat wave, there was 35% increase in hospital admissions for individuals older than 65 years of age. Moreover, adults over the age of 65 have a heat-related death rate that is more than double any other age group. Therefore, with an increasing elderly population that is expected to rise by 60% (to 78 million) by 2035, the causes of this excess mortality must be understood to better protect the ageing United States population. It is notable that selective and non-selective beta blocker drugs are commonly prescribed to older individuals with cardiovascular diseases. In younger individuals exposed to a heat stress, beta blocker administration reduced whole-body sweat rate and skin blood flow responses resulting in greater increases in core body temperature. Notably, nothing is known regarding the effects of beta blockers on thermoregulatory responses during heat exposure in older individuals.

This project will evaluate core body temperature responses to selective and non-selective beta blocker drugs during simulated heat wave exposure in older individuals.
The present invention relates to a medicine for treating hemorrhoids and a preparation thereof. The medicine is mainly prepared by drying and crushing white eulota and borneol. Hemorrhoids can be cured by smearing the made powdered medicine or the ointment at affected parts of hemorrhoids. The medicine is suitable for treating various kinds of hemorrhoids, the effective rate is 100%, and the cure rate is higher than 95%. The medicine has obvious curative effects on treating anal fistula, eczema, etc. The medicine has the advantages of quick curative effect, no pain, high radical treatment rate, no side effect, low price, convenient operation, etc.
The disclosed systems and methods provide hands-free medication tracking. A method includes providing an augmented reality device attachable to a face of a user. The method also includes determining, using one or more sensors of the augmented reality device, a user action to be carried out with respect to a medication. The method also includes presenting, via a display interface of the augmented reality device, a visual indicator to assist with the user action. The method also includes confirming, via the one or more sensors of the augmented reality device, a completion of the user action. The method also includes sending, via a communication interface of the augmented reality device, an update message to a server indicating the completion of the user action, wherein the update message causes the server to update a medication inventory in a database.